Friday, 16 October 2026European Markets

CASINO GUICHARD Stock Impressive Drop 10% So Far On Thursday, Underperforms Market

Loading stream...

(vianews) - shares of casino guichard (cac 40: co.pa) slid by a staggering 10.06% to €6.66 at 13:55 est on thursday, following the last session's downward trend. cac 40 is dropping 0.51% to €7,094.54, after three successive sessions in a row of gains. this seems, up until now, a somewhat negative trend exchanging session today.

casino guichard's last close was €7.41, 61.55% below its 52-week high of €19.27.

about casino guichard

casino, guichard-perrachon s.a. operates as a food retailer in france and internationally. the company operates hypermarkets, supermarkets, shopping centers, and e-commerce sites, as well as convenience, discount, and cash and carry stores. it also offers private label products. in addition, the company is involved in banking, digital marketing and advertising, service station, restaurant, franchise, real estate asset management, property development and trading, rental, banking, and energy-related activities. it operates 10,800 stores. the company was founded in 1898 and is based in saint-étienne, france.

earnings per share

as for profitability, casino guichard has a trailing twelve months eps of €-4.84.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.52%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, casino guichard's stock is considered to be overbought (>=80).

more news about casino guichard (co.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com